Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06411899 is registered in ClinicalTrials.gov with MoonLake Immunotherapeutics AG as lead sponsor.

NCT NCT06411899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06411899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
MoonLake Immunotherapeutics AG
Phase
Phase 3
Overall status
Completed
Start date
May 15, 2024
Completion date
May 14, 2026
Enrollment
422 (actual)
Sites
109

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa